Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia
Status:
Active, not recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of flotetuzumab and how well it
works in treating patients with acute myeloid leukemia that has come back (recurrent) or has
not responded to treatment (refractory). Immunotherapy with flotetuzumab may induce changes
in the body's immune system and may interfere with the ability of leukemia cells to grow and
spread. Giving flotetuzumab may stop the leukemia from growing or shrink for a period of
time, as well as possibly lessening symptoms, such as pain, that are caused by the leukemia.